Copper oxodotreotide Cu-64

Generic Name
Copper oxodotreotide Cu-64
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C65H88CuN14O19S2
CAS Number
1426155-87-4
Unique Ingredient Identifier
N3858377KC
Background

Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over Ga-labeled somatostatin analogs for positron emission tomography (PET). Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. Furthe...

Indication

Copper Cu 64 Dotatate is a radiopharmaceutical used with positron emission tomography(PET) to locate somatostatin receptor-positive neuroendocrine tumors.

Associated Conditions
Somatostatin Receptor Positive Neuroendocrine Tumours
Associated Therapies
-
Clinical Trials
Related News

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

First Posted Date
2023-11-08
Last Posted Date
2024-12-04
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
10
Registration Number
NCT06122610
Locations
🇺🇸

University of Wisconsin - Madison, Madison, Wisconsin, United States

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

First Posted Date
2023-02-02
Last Posted Date
2023-11-22
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
200
Registration Number
NCT05709171
Locations
🇩🇰

Rigshospitalet, Copenhagen, Denmark

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Phase 3
Completed
Conditions
Neuroendocrine Tumors
Interventions
Drug: 64Cu-DOTATATE
First Posted Date
2018-09-17
Last Posted Date
2022-12-22
Lead Sponsor
Radiomedix, Inc.
Target Recruit Count
63
Registration Number
NCT03673943
Locations
🇺🇸

Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy